Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of selinexor when give together
with standard chemotherapy, high dose cytarabine and mitoxantrone hydrochloride, in treating
patients with acute myeloid leukemia. Selinexor may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving selinexor together with standard chemotherapy may be a better
treatment for patients with acute myeloid leukemia.